List view / Grid view

Bristol-Myers Squibb Company

 

news

BMS divests its HIV R&D assets to ViiV Healthcare

18 December 2015 | By Victoria White

ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...